NTRK+ colorectal cancer patients had significantly higher tumor mutation burden (median 53 mutations per megabase[mut/MB], 95% CI: 36.8–68.0 mut/MB), Figure 1C) in comparison to that of the overall colorectal cancer population (median: 7.7 mut/MB, 95% CI: 11.8–14.2 mut/MB, p < 0.0001), NTRK+ non‐CRC solid tumors (lung cancer) (median: 4 mut/MB, 95%CI: 2.4–7.7 mut/MB, p < 0.0001), or CRC samples harboring other oncogenic fusions including ALK, ROS1, and FGFR fusions (median: 6.6 mut/MB, 95%CI: 5.5–13 mut/MB, p < 0.0001, Figure 1C). This evidence concerns the gene ALK and colorectal carcinoma.